Continuous infusion of amphotericin B deoxycholate in the treatment of cryptococcal meningoencephalitis: Analysis of safety and fungicidal activity

Clinical Infectious Diseases

Volumn 50, Issue 5, 2010, Pages

  Falci, Diego Rodrigues ^a   Lunardi, Luciano Weber ^a   Ramos, Carina Guedes ^a   Bay, Mônica Baumgardt ^a   Aquino, Valério Rodrigues ^a   Goldani, Luciano Zubaran ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; FLUCONAZOLE; FLUCYTOSINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNGICIDAL ACTIVITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOKALEMIA; HYPOMAGNESEMIA; KIDNEY FUNCTION; MALE; MENINGOENCEPHALITIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; COLONY COUNT, MICROBIAL; CRYPTOCOCCUS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; FLUCYTOSINE; HIV INFECTIONS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MENINGITIS, CRYPTOCOCCAL; MICROBIAL VIABILITY; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76749112869     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650489     Document Type: Article

References (12)

1. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007;21:2119-2129.
2. 2. Pappalardo MC, Melhem MS. Cryptococcosis: a review of the Brazilian experience for the disease. Rev Inst Med Trop Sao Paulo 2003; 45: 299-305. (Pubitemid 38055601)
3. Peleg AY, Woods ML. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients. J Antimicrob Chemother 2004; 54:803-808.
4. 4. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001; 322: 579-582. (Pubitemid 32234532)
5. 5. Imhof A, Walter RB, Schaffner A. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis 2003;36:943-951. (Pubitemid 36513276)
6. Lewis RE, Wiederhold NP. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy? Clin Infect Dis 2003; 37: 871-872.
7. 7. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-1767. (Pubitemid 38698379)
8. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15-21.
9. 9. Brouwer AE, Teparrukkul P, Pinpraphaporn S, et al. Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J Infect Dis 2005; 192:681-684. (Pubitemid 41099318)
10. Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis 2009;49:702-709.
11. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999;340:764-771.
12. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002;49(Suppl 1):37-41.